Catherine E. Willoughby

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “CXCR2 inhibition enables NASH-HCC immunotherapy”.

CXCR2 inhibition enables NASH-HCC immunotherapy

Gut(2022)10.1136/gutjnl-2021-326259

N/A

4.8DataRank · unranked

230 citations

John B. G. Mackey, Thomas Jamieson, Erik Ramon‐Gil, Thomas M. Drake, Frédéric Fercoq +41 more

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

Journal of Hepatology(2021)10.1016/j.jhep.2021.04.049

N/A

0DataRank · unranked

234 citations

Sara Torrecilla, Huan Wang, Carla Montironi, Marta Piqué‐Gili, Miguel Torres‐Martín +30 more

Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Hepatology(2021)10.1002/hep.32023

N/A

0DataRank · unranked

164 citations

Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp K. Haber +15 more

Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2517

N/A

0DataRank · unranked

78 citations

Catherine E. Willoughby, Marta Piqué-Gili, Carla Montironi, Jordi Abril‐Fornaguera, Judit Peix +8 more

CXCR2 inhibition enables NASH-HCC immunotherapy

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.24.481779

N/A

0DataRank · unranked

3 citations

John B. G. Mackey, Thomas Jamieson, Erik Ramon‐Gil, Thomas M. Drake, Frédéric Fercoq +41 more

Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-22-0335

N/A

0DataRank · unranked

15 citations

Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alexander Rialdi, Ugne Balaseviciute +24 more

Supplementary Figure from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22482765.v1

N/A

0DataRank · unranked

0 citations

Catherine E. Willoughby, Marta Piqué‐Gili, Carla Montironi, Jordi Abril‐Fornaguera, Judit Peix +8 more

Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

(2023)10.1158/1078-0432.c.6530994

N/A

0DataRank · unranked

0 citations

Catherine E. Willoughby, Marta Piqué‐Gili, Carla Montironi, Jordi Abril‐Fornaguera, Judit Peix +8 more

Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice

Molecular Therapy(2020)10.1016/j.ymthe.2020.10.018

N/A

0DataRank · unranked

104 citations

Laura Torrens, Jordi Abril‐Fornaguera, Roser Pinyol, Catherine E. Willoughby, Jeffrey Posey +6 more

Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

(2023)10.1158/1078-0432.c.6530994.v1

N/A

0DataRank · unranked

0 citations

Catherine E. Willoughby, Marta Piqué‐Gili, Carla Montironi, Jordi Abril‐Fornaguera, Judit Peix +8 more